Annovis Bio Inc. (NYSE: ANVS) Phase 3 Alzheimer’s Trial and Q2 2025 Results FAQ
Summary
What is the current status of Annovis Bio’s Phase 3 Alzheimer’s trial?
The pivotal Phase 3 trial in early Alzheimer’s disease (NCT06709014) now includes 76 secured U.S. sites, with 46 actively enrolling, 38 patients dosed, and nearly 200 in screening. Enrollment is progressing on schedule with a 50% screen failure rate as expected.
What recent milestones has Annovis Bio achieved?
Recent milestones include presenting four scientific posters at AAIC 2025, hiring a director of biostatistics, hosting a trial update webcast, and securing global IP coverage for crystal buntanetap.
How did Annovis Bio’s financial performance look in Q2 2025?
As of June 30, 2025, cash and equivalents totaled $17.1 million, up from $10.6 million at year-end 2024. Quarterly R&D expenses were $5.2 million versus $5.8 million in the prior-year period, while G&A expenses declined to $1.1 million from $2.0 million. Net loss per share narrowed to $0.32 from $0.44.
Where can I find more information about Annovis Bio?
For more information, visit www.annovisbio.com and follow them on LinkedIn, YouTube, and X.
What is the significance of Annovis Bio’s Phase 3 Alzheimer’s trial?
The trial represents a critical step in developing a potential therapy for early Alzheimer’s disease, a condition with significant unmet medical needs. Progress in enrollment and securing U.S. sites underscores the company’s commitment to addressing neurodegeneration.
How can investors stay updated on Annovis Bio’s developments?
The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 148567